Sugi Predict

Sugi Predict / Targets / PMM2

PMM2

Phosphomannomutase 2 · O15305 · PMM2 on Sugi Atlas →

2,880 patent compounds predicted against PMM2, 1,716 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2413025 SCHEMBL2413025 1.00 16/20
SCHEMBL2470520 SCHEMBL2470520 0.70 15/20
SCHEMBL8370760 SCHEMBL8370760 0.69 15/20
SCHEMBL2537991 SCHEMBL2537991 1.00 14/20
SCHEMBL2539354 SCHEMBL2539354 1.00 14/20
SCHEMBL8371772 SCHEMBL8371772 0.77 14/20
SCHEMBL8370795 SCHEMBL8370795 0.68 14/20
SCHEMBL8371855 SCHEMBL8371855 0.68 14/20
SCHEMBL8369479 SCHEMBL8369479 0.64 14/20
SCHEMBL1904929 SCHEMBL1904929 0.59 14/20
SCHEMBL2537036 SCHEMBL2537036 1.00 13/20
SCHEMBL2538424 SCHEMBL2538424 1.00 13/20
SCHEMBL6883780 SCHEMBL6883780 0.67 13/20
SCHEMBL1896513 SCHEMBL1896513 0.65 13/20
SCHEMBL7689966 SCHEMBL7689966 0.56 13/20
SCHEMBL7694469 SCHEMBL7694469 0.50 13/20
SCHEMBL1898397 SCHEMBL1898397 1.00 12/20
SCHEMBL8371846 SCHEMBL8371846 0.77 12/20
SCHEMBL1899006 SCHEMBL1899006 0.68 12/20
SCHEMBL8369495 SCHEMBL8369495 0.64 12/20

Clinical trials — most relevant to PMM2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Safety and Efficacy of Avalglucosidase Alfa in Patients With Non-classic Pompe Disease Aged ≥ 5 Years PHASE4ACTIVE_NOT_RECRUITING
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG PHASE2/PHASE3ACTIVE_NOT_RECRUITING
Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive PHASE3UNKNOWN
A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia PHASE3COMPLETED
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG PHASE2COMPLETED
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients PHASE2ENROLLING_BY_INVITATION
The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses PHASE2COMPLETED
The Effect of Triheptanoin in Adults With McArdle Disease (Glycogen Storage Disease Type V) PHASE2COMPLETED
Triheptanoin in Mc Ardle PHASE2COMPLETED
Sodium Valproate for GSDV PHASE2COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy PHASE1COMPLETED
Natural History Study Protocol in PMM2-CDG (CDG-Ia) nanACTIVE_NOT_RECRUITING
Natural History Study of Mitochondrial Myopathy nanRECRUITING
Genetic and Family Studies of Inherited Muscle Diseases nanCOMPLETED
Biomarker for Mannosidosis Disease (BioMannosidosis) nanWITHDRAWN
Biomarker for Glycogen Storage Diseases (BioGlycogen) nanWITHDRAWN
Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia nanUNKNOWN
An MRI Study on Muscular Diseases -Pompe Disease and Dystrophia Myotonica- nanUNKNOWN
Characterization of the Patient Population With Galactosialidosis nanCOMPLETED
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation nanCOMPLETED
Clinical, Biological and NMR Outcome Measures Study for Hereditary Inclusion Body Myopathy Due to Mutation of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine Kinase Gene (GNE) nanCOMPLETED
Study of Muscle Wasting and Altered Metabolism in Patients With Myotonic Dystrophy nanCOMPLETED
The Natural History of Alpha-Mannosidosis nanCOMPLETED
ERT in Pompe Disease: Elucidation of Molecular Structures Contributing to Enzyme Uptake and Immunoreactivity nanUNKNOWN
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism nanNOT_YET_RECRUITING
Digestive Dysmotility in Mitochondrial Neurogastrointestinal Encephalomyopathy nanUNKNOWN
Core Outcome Set for Head, Neck and Respiratory Disease in Mucopolysaccharidosis II nanCOMPLETED
Efficacy and Safety of Vaccination Against COVID-19 in Neuromuscular Patients nanCOMPLETED
Neurometabolic Profile of Individuals With Primary Mitochondrial Disease nanRECRUITING
Identification and Characterization of Monogenic Diabetes nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PMM2 binder may also engage these)

ProteinNameSimilarity
Q60HD6 — 1.000 Q60HD6 →
Q3SZJ9 — 0.990 Q3SZJ9 →
A0A0K9RL25 — 0.989 A0A0K9RL25 →
A0A0U1WZ18 — 0.985 A0A0U1WZ18 →
Q9Z2M7 — 0.985 Q9Z2M7 →
Q92871 — 0.983 Q92871 →
O80840 — 0.982 O80840 →
O35621 — 0.981 O35621 →
Q7XPW5 — 0.977 Q7XPW5 →
Q259G4 — 0.977 Q259G4 →
Q1W374 — 0.976 Q1W374 →
Q1W376 — 0.974 Q1W376 →
Q1W375 — 0.965 Q1W375 →
A0A1S4A695 — 0.965 A0A1S4A695 →
Q1W377 — 0.965 Q1W377 →
Q9D020 — 0.962 Q9D020 →
Q7SYN4 — 0.961 Q7SYN4 →
Q9H0P0 — 0.954 Q9H0P0 →
Q5ZKF6 — 0.952 Q5ZKF6 →
PSPH Phosphoserine phosphatase 0.951 landscape →
NT5C3B 7-methylguanosine phosphate-specific 5'-nucleotidase 0.950 landscape →
Q5ZID6 — 0.950 Q5ZID6 →
Q5RFI8 — 0.949 Q5RFI8 →
Q99LS3 — 0.949 Q99LS3 →
Q5RB83 — 0.948 Q5RB83 →
Q8K183 — 0.947 Q8K183 →
Q3UFY7 — 0.947 Q3UFY7 →
P60028 — 0.947 P60028 →
PGM2 Phosphopentomutase 0.946 landscape →
Q5ZMA6 — 0.946 Q5ZMA6 →